Postsurgical thyroid remnant estimation by 99mTc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma

Head and Neck

Volumn 33, Issue 4, 2011, Pages 552-556

  Giovanella, Luca ^a   Suriano, Sergio ^a   Ricci, Riccardo ^a   Ceriani, Luca ^a   Verburg, Frederik Anton ^b  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

99mTc pertechnetate; ablation; differentiated thyroid carcinoma; radioiodine; thyroidectomy; whole body scan

Indexed keywords

PERTECHNETIC ACID TC 99M; RADIOACTIVE IODINE; THYROGLOBULIN; THYROTROPIN;

ABLATION THERAPY; ADULT; ARTICLE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCINTIGRAPHY; THYROID CARCINOMA; THYROID GLAND; THYROIDECTOMY; THYROIDITIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CARCINOMA; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; SODIUM PERTECHNETATE TC 99M; THYROGLOBULIN; THYROID GLAND; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952968557     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21490     Document Type: Article

References (27)

1. Schlumberger MJ,. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297-306. (Pubitemid 28065257)
2. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803. (Pubitemid 43997716)
3. Verkooijen RB, Stokkel MP, Smit JW, Pauwels EK,. Radioiodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy. Eur J Nucl Med Mol Imaging 2004; 31: 499-506. (Pubitemid 38461564)
4. de Klerk JM, de Keizer B, Zelissen PM, Lips CM, Koppeschaar HP,. Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy. Nucl Med Comm 2000; 21: 529-532.
5. Bajén MT, Mañé S, Muñoz A, García JR,. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants. J Nucl Med 2000; 41: 2038-2042.
6. Verburg FA, Verkoojien RB, Stokkel MP, van Isselt JW,. The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I. Nuklearmedizin 2009; 48: 138-142; quiz N19-20.
7. Gulzar Z, Jana S, Young I, et al. Neck and whole-body scanning with 5-mCi dose of (123)I as diagnostic tracer in patients with well-differentiated thyroid cancer. Endocr Pract 2001; 7: 244-249. (Pubitemid 32707714)
8. Meller J, Becker W,. The continuing importance of thyroid scintigraphy in the era of high-resolution ultrasound. Eur J Nucl Med Mol Imaging 2002; 29 Suppl 2: S425-S438. (Pubitemid 34985341)
9. Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2008; 35: 1941-1959.
10. American Joint Committee on Cancer: Chapter 8: Thyroid, in AJCC cancer staging handbook. 6th edition. Springer, New York; 2002. pp 89-98.
11. Giovanella L,. Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. Clin Chem Lab Med 2008; 46: 1067-1073.
12. Giovanella L, Keller F, Ceriani L, Tozzoli R,. Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma. Clin Chem Lab Med 2009; 47: 952-954.
13. Verburg FA, de Keizer B, Lips CJ, Zelissen PM, de Klerk JM,. Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol 2005; 152: 33-37. (Pubitemid 40185450)
14. Giovanella L, Ceriani L,. High-sensitivity human thyroglobulin (hTG) immunoradiometric assay in the follow-up of patients with differentiated thyroid cancer. Clin Chem Lab Med 2002; 40: 480-484. (Pubitemid 34693089)
15. Nadig MR, Pant GS, Bal C,. Usefulness of 99mTc-pertechnetate single-photon emission computed tomography in remnant mass estimation of postsurgical patients of differentiated thyroid cancer during internal dosimetry. Nucl Med Commun 2008; 29: 809-814.
16. Salvatori M, Perotti G, Rufini V, Maussier ML, Dottorini ME,. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan? Clin Endocrinol (Oxf) 2004; 61: 704-710. (Pubitemid 40006790)
17. Muratet JP, Daver A, Minier JF, Larra F,. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 1998; 39: 1546-1550. (Pubitemid 28459884)
18. Verkooijen RB, Verburg FA, van Isselt JW, Lips CJ, Smit JW, Stokkel MP,. The success rate of I-131 ablation in differentiated thyroid cancer: comparison of uptake-related and fixed-dose strategies. Eur J Endocrinol 2008; 159: 301-307.
19. Kim TY, Kim WB, Kim ES, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005; 90: 1440-1445.
20. Giovanella L, Ceriani L, Ghelfo A, Keller F,. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med 2005; 43: 843-847. (Pubitemid 41461160)
21. Phan HT, Jager PL, van der Wal JE, et al. The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur J Endocrinol 2008; 158: 77-83. (Pubitemid 351211043)
22. Park EK, Chung JK, Lim IH, et al. Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging 2009; 36: 172-179.
23. Spies WG, Wojtowicz CH, Spoies SM, Shah AY, Zimmer AM,. Value of post-therapy whole-body I-131 imaging in the evaluation of patients with thyroid carcinoma having undergone high-dose I-131 therapy. Clin Nucl Med 1989; 14: 793-800. (Pubitemid 20020131)
24. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R,. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998; 228: 320-330. (Pubitemid 30191695)
25. Bal CS, Kumar A, Chandra P, Dwivedi SN, Pant GS,. A prospective clinical trial to assess the efficacy of radioiodine ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer undergoing sub-total thyroidectomy. Acta Oncol 2006; 45: 1067-1072. (Pubitemid 44808492)
26. Arad E, O'Mara RE, Wilson GA,. Ablation of remaining functioning thyroid lobe with radioiodine after hemithyroidectomy for carcinoma. Clin Nucl Med 1993; 18: 662-663. (Pubitemid 23229598)
27. Haenel LC IV, Gordon BM, Sagel J,. Radioiodine-induced thyrotoxicosis and thyroiditis after ablative therapy for papillary carcinoma: a case discussion and literature review. Clin Nucl Med 1999; 24: 741-743. (Pubitemid 29449626)